A groundbreaking international collaboration, fortified by a prestigious pan-European EUREKA grant, has been officially launched to pioneer the development of highly targeted small-molecule therapies for hyper-inflammatory diseases. This ambitious initiative specifically focuses on conditions driven by dysregulated neutrophil activity, including the debilitating inflammatory bowel disease (IBD). The partnership, announced on February 11, brings together the distinct strengths of Evogene (Nasdaq: EVGN), Systasy Bioscience, and LMU University Hospital Munich, with crucial additional participation from the esteemed Weizmann Institute of Science. This formidable alliance aims to address a significant unmet therapeutic need by integrating cutting-edge AI-powered molecular design, advanced iPSC-based functional profiling, and profound clinical expertise in rare immunodeficiencies.
Addressing the Unmet Need in Inflammatory Diseases
Inflammatory diseases represent a vast and complex spectrum of conditions affecting hundreds of millions of people globally. These diseases, often chronic and debilitating, arise from an overactive or misdirected immune response, leading to tissue damage and a wide array of symptoms. Neutrophils, a type of white blood cell, are among the earliest and most abundant immune cells to respond to sites of inflammation. While essential for fighting infections, their dysregulated or excessive activity is a key driver of tissue damage and pathology in a broad range of immune-mediated conditions, including rheumatoid arthritis, psoriasis, and notably, inflammatory bowel disease.
Current therapeutic approaches for many inflammatory conditions often involve broad immunosuppression, which, while effective in mitigating symptoms, can leave patients vulnerable to infections and carry significant side effects. The partners in this new collaboration argue that existing treatments frequently fail to directly and selectively target neutrophil-driven inflammation. This critical gap in targeted therapy leaves many patients with suboptimal outcomes and a reduced quality of life, underscoring the urgency and potential impact of this novel research direction. The goal is to develop therapies that can precisely modulate the pathogenic activity of neutrophils without compromising the broader immune system, thereby offering a safer and more effective treatment paradigm.
The Scientific Genesis: A Rare Immunodeficiency as a Blueprint
The scientific foundation of this collaboration is rooted in the pioneering work of Professor Christoph Klein at LMU’s Dr. von Hauner Children’s Hospital. Professor Klein’s research group made a pivotal discovery by identifying a rare genetic immunodeficiency. Intriguingly, individuals with this specific condition exhibited significantly reduced neutrophil counts but, critically, did not suffer from significant functional immune impairment. This observation provided a profound insight: it suggested that it might be possible to modulate neutrophil activity or numbers to therapeutic effect without inducing the broad immune suppression typically associated with conventional treatments.
As Professor Klein articulated, "We care for children with rare diseases every day; occasionally, we discover novel genetic defects and elucidate pathomechanisms. Only rarely, however, is clinical and scientific knowledge translated into the development of novel therapeutic strategies." His statement underscores the rarity and significance of identifying a naturally occurring biological phenomenon that offers a clear, actionable path toward a new therapeutic strategy. The collaboration’s core aim is to translate this naturally occurring biology—the ability to reduce neutrophil counts or activity while preserving overall immune function—into a viable therapeutic strategy for hyper-inflammatory diseases. This approach promises a paradigm shift, moving beyond indiscriminate immune suppression towards a more nuanced, targeted intervention that could selectively dampen excessive neutrophil-driven inflammation.
A Synergistic Alliance: Partner Contributions
The success of such an ambitious undertaking hinges on the complementary expertise and advanced technological platforms contributed by each partner. This international consortium represents a strategic convergence of computational power, advanced biological profiling, and deep clinical understanding.
Evogene (Nasdaq: EVGN) and ChemPass AI: Evogene, an Israeli computational biology company, takes the lead in the small-molecule discovery effort. At the heart of its contribution is its proprietary ChemPass AI generative engine. This sophisticated artificial intelligence platform is designed to rapidly and efficiently design, optimize, and prioritize novel small-molecule inhibitors. ChemPass AI leverages advanced machine learning algorithms to explore vast chemical spaces, predict molecular properties, and identify compounds with desired biological activities, significantly accelerating the initial stages of drug discovery that traditionally are time-consuming and resource-intensive. Evogene’s involvement highlights the increasing role of AI in revolutionizing pharmaceutical R&D, moving from hypothesis-driven experimentation to data-driven discovery.
Systasy Bioscience and PathwayProfiler: Systasy Bioscience brings its cutting-edge PathwayProfiler platform to the collaboration. This platform, built on proprietary DNA barcoding technology, is crucial for generating multiplexed functional data from stem cell-derived neutrophils. By utilizing induced pluripotent stem cells (iPSCs), Systasy can create human neutrophil models in a controlled laboratory setting, allowing for high-throughput screening and detailed functional profiling. The PathwayProfiler platform provides high-dimensional readouts, offering comprehensive insights into how potential drug candidates interact with neutrophil pathways. This experimental validation loop is vital; it allows the collaborators to test and refine the AI-designed candidates, ensuring that computational predictions translate into demonstrable biological effects, thereby closing the gap between in silico design and in vitro efficacy.
LMU University Hospital Munich (Prof. Christoph Klein): Beyond providing the foundational scientific rationale, LMU University Hospital Munich, under the guidance of Professor Klein, plays a critical role in the clinical and translational aspects of the project. LMU will be responsible for validating lead compounds in sophisticated human in vitro neutrophil models, ensuring that the promising candidates demonstrate efficacy and safety in human biological systems. Furthermore, their expertise will be instrumental in biomarker discovery, identifying measurable indicators that can track disease progression and therapeutic response, which is crucial for both preclinical development and future clinical trials. LMU’s involvement bridges the gap between basic scientific discovery and its practical application in a clinical setting, ensuring the project remains focused on patient benefit.
Weizmann Institute of Science: The Weizmann Institute of Science, a globally recognized multidisciplinary research institution, will support the high-throughput experimental validation process. Their expertise in advanced screening technologies and experimental methodologies will be integrated directly with the computational design process. This integration is key to rapidly iterating on candidate molecules, providing quick feedback loops to the ChemPass AI engine, and accelerating the optimization of lead compounds. The Weizmann Institute’s involvement underscores the interdisciplinary nature of modern drug discovery, where computational power is seamlessly integrated with robust experimental validation.
The EUREKA Grant: A Catalyst for Cross-Border Innovation
The funding framework for this ambitious collaboration is provided by a EUREKA grant, a pan-European intergovernmental initiative dedicated to supporting market-oriented cross-border R&D projects. The EUREKA program fosters international collaboration and accelerates the development of innovative products, processes, and services with global market potential.
Ofer Haviv, Evogene’s President and CEO, remarked on the significance of this support: "The support of the prestigious EUREKA grant is a strong vote of confidence in this synergistic collaboration, as well as further acknowledgment of the uniqueness of ChemPass AI." This grant not only provides essential financial backing but also serves as a robust endorsement of the scientific merit and commercial potential of the project. It validates the innovative approach of combining AI-driven drug discovery with cutting-edge biological validation and clinical insights. Such grants are instrumental in facilitating international scientific exchange, pooling resources, and accelerating research that might otherwise be too costly or complex for individual entities to pursue alone. While specific financial terms were not disclosed, the backing of EUREKA signifies a substantial investment in a project deemed capable of delivering significant societal and economic impact.
Evogene’s Expanding Footprint in AI-Driven Pharma
The announcement of this collaboration follows a particularly productive period for Evogene’s pharmaceutical partnerships, signaling its growing prominence in the AI-driven drug discovery landscape. Just in January, the company unveiled a collaboration with Unravel Biosciences, another strategic alliance aimed at developing a first-in-class small-molecule therapy specifically designed to reverse neurological damage in demyelinating disorders. This partnership demonstrates Evogene’s versatility and the broad applicability of its AI platforms across diverse therapeutic areas.
Further solidifying its technological leadership, Evogene also expanded its strategic partnership with Google Cloud in the same week as the LMU/Systasy announcement. This expanded collaboration focuses on integrating advanced AI agents into the ChemPass AI platform, aiming to pioneer a generative AI foundation model for novel small-molecule design. This move highlights Evogene’s commitment to continuously enhancing its AI capabilities, leveraging the latest advancements in artificial intelligence to push the boundaries of drug discovery and development. These recent developments underscore Evogene’s strategic vision to become a leading player in the AI-driven pharmaceutical space, forging key alliances and continuously innovating its technological core.
The Global Burden of Inflammatory Bowel Disease (IBD)
The primary focus on inflammatory bowel disease (IBD) within this collaboration highlights the significant global health challenge posed by this group of chronic inflammatory conditions, primarily Crohn’s disease and ulcerative colitis. IBD affects millions worldwide, with estimates varying by source and methodology. Widely cited analyses indicate that roughly 6.8 million people were affected by IBD in 2017, and incidence rates are notably rising in newly industrialized countries, suggesting an interplay of genetic predispositions and environmental factors, including diet and lifestyle changes associated with urbanization and industrialization.
IBD is characterized by chronic inflammation of the gastrointestinal tract, leading to debilitating symptoms such as severe abdominal pain, persistent diarrhea, fatigue, weight loss, and in severe cases, life-threatening complications. The chronic nature of IBD significantly impacts patients’ quality of life, often requiring lifelong management. Current treatments, including anti-inflammatory drugs, immunosuppressants, and biologics, can induce remission and manage symptoms but are not curative. Many patients experience treatment failure, develop resistance over time, or suffer from significant side effects, reinforcing the urgent need for novel, more effective, and safer therapeutic options. A targeted therapy that specifically modulates neutrophil activity without broad immunosuppression could represent a major breakthrough for IBD patients, offering a new pathway to disease management with potentially fewer adverse effects and improved long-term outcomes.
Broader Implications and Future Outlook
This collaboration marks a significant step forward in the field of drug discovery and translational medicine. The integration of artificial intelligence, advanced stem cell technology, and deep clinical insights embodies the future of pharmaceutical research. The potential to selectively modulate neutrophil-driven inflammation could represent a paradigm shift, moving beyond the broad immunosuppression that defines many current treatments for inflammatory and autoimmune diseases.
Accelerated Drug Discovery: AI platforms like Evogene’s ChemPass AI promise to dramatically accelerate the early stages of drug discovery, reducing the time and cost associated with identifying promising lead compounds. By efficiently navigating vast chemical spaces and predicting molecular properties, AI can guide researchers toward optimal candidates much faster than traditional methods.
Precision Medicine: The targeted nature of this approach aligns perfectly with the principles of precision medicine. By focusing on specific cellular mechanisms (dysregulated neutrophil activity) rather than general immune suppression, the collaboration aims to develop therapies that are not only more effective but also safer, minimizing off-target effects and improving patient tolerability.
Translational Impact: The direct involvement of LMU University Hospital Munich and Professor Klein’s clinical expertise ensures that the research remains firmly anchored in clinical relevance. The journey from identifying a rare genetic immunodeficiency to translating that biological insight into a novel therapeutic strategy exemplifies the power of translational medicine – bridging the gap between basic scientific discovery and real-world patient benefit.
Global Health Impact: Success in this endeavor could have far-reaching implications, not only for IBD patients but potentially for other hyper-inflammatory conditions where neutrophils play a pathogenic role. Developing a new class of small-molecule therapies for these diseases could offer hope to millions worldwide who currently struggle with limited or inadequate treatment options.
While the path from discovery to a marketed drug is long and arduous, involving extensive preclinical and clinical trials, the foundation laid by this collaboration is robust. The synergistic blend of computational prowess, biological innovation, and clinical leadership, backed by a prestigious EUREKA grant, positions this team at the forefront of a new era in the fight against inflammatory diseases. This initiative promises to unlock novel therapeutic avenues, ultimately improving the lives of countless patients globally.
Leave a Reply